- Report
- May 2024
- 130 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 300 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- October 2024
- 331 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- February 2022
- 220 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Report
- October 2023
- 137 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- February 2019
- 19 Pages
Global
From €9544EUR$10,000USD£7,996GBP
- Drug Pipelines
- February 2018
- 19 Pages
Global
From €9544EUR$10,000USD£7,996GBP
Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) used in the treatment of cardiovascular diseases. It is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type 2 diabetes. Finerenone is the first MRA to be approved for use in the United States and Europe. It works by blocking the action of aldosterone, a hormone that can cause fluid retention and high blood pressure.
Finerenone is a promising new treatment option for patients with CKD and type 2 diabetes, as it has been shown to reduce the risk of cardiovascular death and hospitalization for heart failure. It is also being studied for its potential to reduce the risk of stroke and other cardiovascular events.
Companies in the Finerenone market include Bayer, Merck, Novartis, and AstraZeneca. Show Less Read more
